Thinking of Investing in RDY? What Our Analysts Know.

By Scott Lee • Tuesday, August 05 10:08 • Permanent Link

Large-cap Health Care company Dr. Reddy's Laboratories Ltd has moved -0.6% so far today on a volume of 67,482, compared to its average of 1,631,387. In contrast, the S&P 500 index moved -0.0%.

Dr. Reddy's Laboratories Ltd trades -8.46% away from its average analyst target price of $14.98 per share. The 4 analysts following the stock have set target prices ranging from $11.587726 to $18.51123, and on average have given Dr. Reddy's Laboratories Ltd a rating of buy.

If you are considering an investment in RDY, you'll want to know the following:

Dr. Reddy's Laboratories Ltd's current price is 49.5% above its Graham number of $9.17, which implies that at its current valuation it does not offer a margin of safety
Dr. Reddy's Laboratories Ltd has moved -15.6% over the last year, and the S&P 500 logged a change of 20.8%
Based on its trailing earnings per share of 0.78, Dr. Reddy's Laboratories Ltd has a trailing 12 month Price to Earnings (P/E) ratio of 17.6 while the S&P 500 average is 29.3
RDY has a forward P/E ratio of 15.8 based on its forward 12 month price to earnings (EPS) of $0.87 per share
Its Price to Book (P/B) ratio is 0.03 compared to its sector average of 3.19
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Based in Hyderabad, the company has 27,811 full time employees and a market cap of $11.62 Billion. Dr. Reddy's Laboratories Ltd currently returns an annual dividend yield of 58.0%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.